# Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury

> **NCT06096415** · PHASE2 · UNKNOWN · sponsor: **Abalonex, LLC** · enrollment: 45 (estimated)

## Conditions studied

- Traumatic Brain Injury
- Cerebral Edema

## Interventions

- **DRUG:** ABX-101 1mg
- **DRUG:** ABX-101 2mg

## Key facts

- **NCT ID:** NCT06096415
- **Lead sponsor:** Abalonex, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-04
- **Final completion:** 2024-05
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06096415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06096415, "Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06096415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*